Unnatural Products in Pact With Novartis to Develop Macrocyclic Peptide Therapeutics
By Amira McKee
Unnatural Products unveiled a deal with Novartis worth up to $1.8 billion to develop macrocyclic peptide therapeutics.
The biotechnology company developing macrocyclic peptides to address previously undruggable targets said Wednesday that it had entered a research collaboration and licensing agreement with Novartis for an undisclosed program.
The collaboration joins Unnatural Products's AI-enhanced macrocycle discovery engine and Novartis' development and commercialization capabilities to create therapeutics with potential applications for cardiovascular disease, the company said.
Under the agreement, Unnatural Products will receive up to $100 million in upfront and pre-investigational new drug milestone payments. In addition, the company may receive up to $1.7 billion in development, regulatory and commercial milestones.
Novartis will take responsibility for IND-enabling studies and all subsequent clinical development, manufacturing and global commercialization of products emerging from the collaboration, Unnatural Products said.
"Novartis has built a highly respected engine in cardiovascular innovation, and we are excited to collaborate with them to unlock the full therapeutic potential of this asset," Unnatural Products Chief Executive Cameron Pye said.
Write to Amira McKee at amira.mckee@wsj.com
(END) Dow Jones Newswires
February 18, 2026 11:02 ET (16:02 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
United States